Results 31 to 40 of about 392,226 (299)

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

open access: yes, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal   +17 more
core   +2 more sources

Factors related to patient propensity to receive adjuvant chemotherapy and outcomes in stage III gastric cancer cases after D2 surgery

open access: yesAsian Journal of Surgery, 2019
Summary: Background: Radical gastrectomy and extended lymph node (D2) dissection followed by adjuvant chemotherapy is the optimal treatment for patients with stage III gastric cancer in Asian population.
Jen-Shi Chen   +6 more
doaj   +1 more source

Characterisation of the immune-related transcriptome in resected biliary tract cancers [PDF]

open access: yes, 2017
Although biliary tract cancers (BTCs) are known to have an inflammatory component, a detailed characterisation of immune-related transcripts has never been performed.
Braconi, Chiara   +19 more
core   +3 more sources

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma

open access: yesFrontiers in Oncology, 2022
BackgroundAdjuvant chemotherapy has been shown to produce a favorable prognosis for patients with resectable mucosal melanoma (MM), resulting in the need for stratification to optimally select patients to benefit from adjuvant therapy.
Lirui Tang   +21 more
doaj   +1 more source

Adjuvant chemotherapy for medulloblastoma [PDF]

open access: yesCancer, 1985
The use of adjuvant chemotherapy for cerebellar medulloblastoma is controversial. Twenty-one children and adolescents were treated with adjuvant low-dose cyclophosphamide and vincristine following surgery and radiotherapy. With a mean observation period of 6 years, the disease-free survival is 81%.
S, McIntosh   +7 more
openaire   +2 more sources

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

open access: yes, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo   +7 more
core   +2 more sources

Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial

open access: yesBMC Cancer, 2018
Background Some patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line treatment for advanced/metastatic ...
Seiji Ito, Yasuo Ohashi, Mitsuru Sasako
doaj   +1 more source

The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder cancer

open access: yesFrontiers in Oncology
The management of muscle-invasive bladder cancer (MIBC) remains a challenging topic since it is witnessing rapidly evolving changes and new drug approvals. In fact, more effective approaches are now available to improve the outcomes of patients with MIBC
Joseph Kattan   +3 more
doaj   +1 more source

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer : randomized clinical trial [PDF]

open access: yes, 2013
BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin ...
Bois, Andreas du   +13 more
core   +1 more source

The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study

open access: yesBMC Cancer, 2023
Background Adjuvant chemotherapy is recommended as the standard treatment for patients with stage II/III resected gastric cancer. However, it is unclear whether older patients also benefit from an adjuvant chemotherapy strategy.
Yu-Hsuan Shih   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy